The product will be launched in Germany and Denmark in the coming weeks, followed soon by Ireland, the UK and the rest of EU, and when approved also in other countries around the world. Its co-marketing partners will market the new drug in selected countries under their own brands.
The product is licensed for the treatment of essential hypertension in patients whose blood pressure is not adequately controlled on MicardisPlus 80/12.5 (80mg telmisartan/12.5mg hydrochlorothiazide) or patients who have been previously stabilized on telmisartan and hydrochlorothiazide separately at the same dosages.